By
Lorenzo Guglielmetti, Marcus Low, Lindsay McKenna
Published: May 4, 2020, 11:19 p.m.·
Tags:
Drug-resistant TB,
Treatment
"Ultimately, high-quality evidence to guide regulatory and policy decision-making must come from adequately designed (and funded) RCTs [randomized controlled trials]–the highest attainable standard of medical evidence, which we owe to patients affected by drug-resistant tuberculosis to strive for and maintain."
Read More →